GET DAILY SIGNALSCollPlant Biotechnologies (CLGN) +19% Climb: Photonics Pivot in Focus
Key Takeaways
- CollPlant Biotechnologies (CLGN) shares climbed roughly 19% over the past 30 days, rising from about $3.91 to a closing price of $4.66.
- The advance was driven by the company's expansion into photonic computing through its LightSolver subsidiary and a proposed corporate rebrand to OptiPhi Computing.
- A proposed Nasdaq ticker change from CLGN to OPHI and a series of LightSolver milestones, including a paid collaboration with Israel's Ministry of Defense, reinforced investor interest.
- Over the trailing quarter, shares have risen sharply from around $3.20, reflecting a strategic repositioning from regenerative medicine into deep-tech photonic computing.
- The company remains pre-revenue at scale, with limited trailing-twelve-month revenue and ongoing net losses, making the stock highly volatile and speculative.
- Get more details on CLGN's Price Targets, Earnings, and Forecast on additional pages to complement this analysis.
- Explore Trending AI Robots to see how AI-driven trading systems are monitoring tickers like CLGN.
CollPlant Biotechnologies (CLGN) Background and Current Positioning
CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) is headquartered in Rehovot, Israel. Historically a regenerative and aesthetic medicine company, CollPlant develops products based on plant-derived recombinant human collagen (rhCollagen), including dermal and soft-tissue fillers, wound-care and tendinopathy products, and bioinks used in 3D bioprinting. Following its September 2026 acquisition of LightSolver Ltd., the company has begun repositioning itself around photonic computing, with LightSolver's all-optical Laser Processing Unit (LPU) targeting high-performance computing, artificial intelligence, aerospace, and financial-engineering workloads. CollPlant retains its rhCollagen and bioink assets while pursuing the computing opportunity, giving the stock exposure to two distinct technology narratives. Investors follow the company for the optionality of this deep-tech pivot as well as its early partnerships and government-backed collaborations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CLGN Stock Price Moves: Last 30 Days and the Broader Quarter
Over the last 30 days, CLGN advanced from a closing price of approximately $3.91 to $4.66, a gain of roughly 19%. The move was uneven, punctuated by sharp single-session rallies rather than a steady climb. Shares jumped from $3.95 to $4.40 on October 29 following news of a paid defense collaboration, and then rose from $3.96 to $4.66 on November 12 — a one-day increase of about 17.7% — after the company confirmed its upcoming Nasdaq ticker change.
The broader quarterly trend has been even more pronounced. From a mid-August level near $3.20, shares have risen to $4.66, a gain of roughly 45% over the trailing three months. That advance followed a period of extreme volatility in late August and early September, when trading volume spiked dramatically. The stock's 52-week range of roughly $2.64 to $22.50 underscores how much the share price has compressed from prior highs even as the recent momentum has turned positive.
Drivers Behind the Recent 30-Day Advance
The 30-day rally was powered almost entirely by the company's pivot toward photonic computing rather than its legacy collagen business. The catalyst sequence began on October 29, when CollPlant announced that LightSolver had secured a paid collaboration with the Israel Ministry of Defense to develop photonic computing technology, sending shares up more than 11% in a single session.
On November 4, the company announced that its board had approved a proposal to change its name to OptiPhi Computing Ltd., subject to shareholder approval, and to change its Nasdaq ticker symbol from CLGN to OPHI. In the following days, LightSolver disclosed an approximately $1.8 million grant from the Israel Innovation Authority to advance its Laser Processing Unit, and separately announced it would unveil the first public demonstration of its all-optical computer at the SC26 supercomputing conference. The rally culminated on November 12, when CollPlant confirmed that its shares would begin trading under the new OPHI ticker effective November 13. The repositioning toward a "computing with light" identity, combined with a series of validating milestones, reframed CLGN as an AI-adjacent deep-tech story in the eyes of investors.
Quarterly Performance and the Strategic Shift
The quarterly trend reflects a fundamental transformation of the company's strategy. The defining event was the September 2026 acquisition of LightSolver, which shifted the center of gravity from collagen-based regenerative medicine to all-optical computing. That transaction, followed by the proposed rebrand to OptiPhi Computing, positioned the company within the broader theme of next-generation computing hardware as demand for AI and high-performance computing capacity accelerates.
Supporting milestones reinforced the narrative over the quarter, including a strategic partnership with Boeing to develop a laser-based accelerator for engineering simulation, funding from the European Innovation Council, peer-reviewed research with the High-Performance Computing Center Stuttgart, and the defense collaboration announced in late October. A roughly $3.7 million private placement also provided incremental capital. Because the company is small, thinly traded, and pre-revenue at scale, each announcement has produced outsized share-price reactions in both directions.
CLGN Stock Outlook: Key Events on the Horizon
Several near-term events could shape CLGN's trajectory. The extraordinary general meeting scheduled for November 24 will determine whether shareholders approve the name change to OptiPhi Computing, with the ticker transition to OPHI already underway. The first public demonstration of LightSolver's all-optical computer at the SC26 conference will be closely watched as a test of the technology's commercial promise, as will any follow-on partnerships, grants, or government contracts for the LPU platform.
Investors should also monitor the company's cash position and financing activity, given its limited revenue and continued operating losses, as well as quarterly earnings updates and any guidance on the pace of LPU commercialization. Broader sentiment toward AI and high-performance computing hardware, competitive developments in photonic and optical computing, and overall risk appetite for speculative, small-cap technology names are additional factors likely to influence the stock. As with any pre-revenue deep-tech company, execution risk remains significant. From what I see, tracking these catalysts closely will be important in the weeks ahead.
Exploring AI Tools for Market Monitoring
In my analysis of names like CLGN, I often turn to Tickeron’s AI Trading Bots for additional perspective. These systems provide a data-driven way to observe how automated strategies respond to volatility and news flow in real time, helping me cross-check my own observations without replacing independent judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CLGN in +19.33% Uptrend, advancing for three consecutive days on November 12, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CLGN advanced for three days, in 168 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on CLGN as a result. In 68 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CLGN just turned positive on October 08, 2026. Looking at past instances where CLGN's MACD turned positive, the stock continued to rise in 33 of 43 cases over the following month. The odds of a continued upward trend are 77%.
CLGN moved above its 50-day moving average on November 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CLGN crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 60 of 81 cases where CLGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for CLGN moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CLGN broke above its upper Bollinger Band on November 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.560) is normal, around the industry mean (3.498). P/E Ratio (-3.875) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.494) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. CLGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medical devices
Industry Biotechnology
Advertisement